Bertil Lindmark
Equibles does not estimate personal net worth.
About Bertil Lindmark
Damora Therapeutics, Inc. reported in an 8-K filed September 26, 2023 that Bertil Lindmark was terminated as Chief Medical Officer, effective September 21, 2023. The proxy statement of Damora Therapeutics, Inc. reports total compensation of $819,618 for Bertil Lindmark in fiscal 2023, including a base salary of $335,808. Disclosed compensation is on record for 3 fiscal years.
“on September 21, 2023, the Company informed Bertil Lindmark, M.D., the Company's Chief Medical Officer, that his position will be eliminated and that his duties will be assumed by Hans Schambye, M.D., Ph.D., the Company's Chief Executive Officer.”
Affiliation history
-
Damora Therapeutics, Inc. (DMRA)
Proxy statement
Start not stated–2023-09-21
-
Damora Therapeutics, Inc. (DMRA)
Proxy statement
Start not stated–2023-09-26
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Damora Therapeutics, Inc. (DMRA) | M.D., Ph.D. Former Chief Medical Officer | $335,808 | $819,618 |
| 2022 | Damora Therapeutics, Inc. (DMRA) | M.D., Ph.D. Former Chief Medical Officer | $417,260 | $814,998 |
| 2020 | Damora Therapeutics, Inc. (DMRA) | M.D., Ph.D.^(^^4)^ Chief Medical Officer | $378,772 | $812,929 |